Building the leading pharmacological stabilizer company for the treatment of rare diseases.
Congruence Therapeutics is a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding. Using structural bioinformatics, computational chemistry, and machine learning, the Company deploys an in silico platform that enables the design of new pharmacological stabilizers, a validated class of small molecules, at an unprecedented speed and scale.
We’re looking to fill openings immediately! We’re building a world-class team of drug hunters to efficiently design small molecules for rare diseases with high unmet medical need.
Drug hunters apply here
Congruence closes Series A funding round
The US$50M Series A financing was led by Amplitude Ventures and Fonds de solidarité FTQ, with participation from Lumira Ventures, Investissement Quebec, OrbiMed Advisors, Driehaus and others.
Need to reach us?
If you are interested in a biology position and want to learn more, contact Kenneth Valenzano Ph.D, Chief Scientific Officer.
If you are interested in a Chemistry position and want to learn more, contact Lee Fader Ph.D., Vice President Chemistry.
Need to reach us?
If you are interested in a biology position and want to learn more, contact Kenneth Valenzano Ph.D, Chief Scientific Officer.
If you are interested in a Chemistry position and want to learn more, contact Lee Fader Ph.D., Vice President Chemistry.